Mohamed Farahidah, van der Walle Christopher F
Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 27 Taylor Street, Glasgow, UK.
J Pharm Sci. 2008 Jan;97(1):71-87. doi: 10.1002/jps.21082.
Poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) microspheres and nanoparticles remain the focus of intensive research effort directed to the controlled release and in vivo localization of drugs. In recent years engineering approaches have been devised to create novel micro- and nano-particles which provide greater control over the drug release profile and present opportunities for drug targeting at the tissue and cellular levels. This has been possible with better understanding and manipulation of the fabrication and degradation processes, particularly emulsion-solvent extraction, and conjugation of polyesters with ligands or other polymers before or after particle formation. As a result, particle surface and internal porosity have been designed to meet criteria-facilitating passive targeting (e.g., for pulmonary delivery), modification of the drug release profile (e.g., attenuation of the burst release) and active targeting via ligand binding to specific cell receptors. It is now possible to envisage adventurous applications for polyester microparticles beyond their inherent role as biodegradable, controlled drug delivery vehicles. These may include drug delivery vehicles for the treatment of cerebral disease and tumor targeting, and co-delivery of drugs in a pulsatile and/or time-delayed fashion.
聚乳酸(PLA)和聚乳酸 - 乙醇酸共聚物(PLGA)微球与纳米颗粒仍然是药物控释和体内定位相关密集研究工作的重点。近年来,已经设计出工程方法来制造新型的微米和纳米颗粒,这些颗粒能够更好地控制药物释放曲线,并为组织和细胞水平的药物靶向提供机会。这得益于对制造和降解过程(特别是乳液 - 溶剂萃取)有了更好的理解和操控,以及在颗粒形成之前或之后将聚酯与配体或其他聚合物进行共轭。结果,颗粒的表面和内部孔隙率已被设计成符合促进被动靶向(例如用于肺部给药)、改变药物释放曲线(例如减弱突释)以及通过配体与特定细胞受体结合实现主动靶向等标准。现在可以设想聚酯微粒除了作为可生物降解的控释药物载体的固有作用之外的大胆应用。这些应用可能包括用于治疗脑部疾病和肿瘤靶向的药物递送载体,以及以脉冲和/或延时方式共同递送药物。